Evidence map›Paper›PMID 42131291›Full record

ArticleHemaSphere2026

CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment.

Brian Ringhofer, Wolfram Polzer, Michaela Prchal-Murphy, Eszter Doma, Sebastian Kollmann, Elisabeth Gamper, Jonatan Kendler, Belinda S Maw, Eva Zebedin-Brandl, Juan Li and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Brian RinghoferDepartment of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.
Wolfram PolzerDepartment of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.
Michaela Prchal-MurphyDepartment of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.
Eszter DomaDepartment of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.
Sebastian KollmannDepartment of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.
Elisabeth GamperDepartment of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.ORCID https://orcid.org/0009-0007-8439-4148
Jonatan KendlerDepartment of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.ORCID https://orcid.org/0000-0002-2470-4868
Belinda S MawDepartment of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.
Eva Zebedin-BrandlDepartment of Physiology and Pharmacology Medical University of Vienna Vienna Austria.
Juan LiDepartment of Haematology, Cambridge Stem Cell Institute, Jeffery Cheah Biomedical Center University of Cambridge Cambridge UK.
Anthony R GreenDepartment of Haematology, Cambridge Stem Cell Institute, Jeffery Cheah Biomedical Center University of Cambridge Cambridge UK.
Maria-Theresa KrauthDepartment of Internal Medicine I, Division of Hematology and Hemostaseology Medical University of Vienna Vienna Austria.
Emir HadzijusufovicDepartment of Internal Medicine I, Division of Hematology and Hemostaseology Medical University of Vienna Vienna Austria.
Daniel IvanovDepartment of Internal Medicine I, Division of Hematology and Hemostaseology Medical University of Vienna Vienna Austria.
Peter ValentDepartment of Internal Medicine I, Division of Hematology and Hemostaseology Medical University of Vienna Vienna Austria.
Gregor HoermannMLL Munich Leukemia Laboratory Munich Germany.
Thorsten KlampflDepartment of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.
Veronika SexlUniversity of Innsbruck Innsbruck Austria.
Karoline KollmannDepartment of Biological Sciences and Pathobiology, Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna Vienna Austria.ORCID https://orcid.org/0000-0002-7937-4245

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interferon-α (IFNα) remains a potent therapeutic option for myeloproliferative neoplasms (MPNs) with an activated JAK/STAT signaling axis. However, variable patient responses highlight the need for optimized combination strategies. Recent studies suggest a link between cyclin-dependent kinase 6 (CDK6) and IFN signaling. Here, we investigated whether CDK6 inhibition might play a role in IFN responsiveness in MPN cells. Using

Identifiers

PMID42131291
PMCPMC13162134

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.